FOR IMMEDIATE RELEASE:
Datexim Revolutionizes Cytology with CytoProcessor® 3.3 Launch at ECDP and Celebrates 800,000 Exams Milestone

Caen, France – June 17, 2025 –
Datexim, a leading innovator in digital pathology solutions, will promote, at the European Congress of Digital Pathology, the release of CytoProcessor® 3.3, the latest version of its CE-marked IVD device. This significant update enhances laboratory efficiency and data management for healthcare professionals. The company also proudly celebrates a major milestone: 800,000 examinations processed in clinical routine using the CytoProcessor® platform with a strong acceleration since 2024.

CytoProcessor® 3.3 introduces a suite of new features designed to streamline workflows and improve diagnostic accuracy:
• New User Interface for streamlined navigation
• Advanced Microorganism Classifier powered by deep learning
• DICOM Support and new scanner support
• Bidirectional LIS integration: LIS can now trigger actions to CytoProcessor®
• Customizable archiving management: flexible archiving policies at slide level as well as laboratory level
• Structured Reporting: All analyses for each slide, including cell classification and microorganism detection, are now consolidated into one comprehensive report.

"We are thrilled to launch CytoProcessor® 3.3, which represents our ongoing commitment to providing cutting-edge solutions that empower healthcare professionals in their critical work," said Arnaud Renouf, CEO of Datexim. "The new features in version 3.3 were developed in direct response to feedback from our users, ensuring we continue to meet the evolving needs of modern cytology laboratories."
The launch of CytoProcessor® 3.3 coincides with a remarkable achievement for Datexim: 800,000 cases successfully processed in clinical routine using the CytoProcessor® platform across multiple laboratories in Europe. This milestone underscores the platform's reliability, accuracy, and widespread adoption in the healthcare community.
Arnaud Renouf further reflected on this significant journey, stating, "From being the world's first IVD certified AI tool for cervical cancer screening in 2017 to reaching 800,000 processed exams today, this milestone is a profound testament to the dedication of our team and the trust of our clinical partners. It reinforces our vision of leveraging artificial intelligence to deliver impactful and reliable solutions that truly make a difference in patient care."

CytoProcessor® is a CE marked IVD device, intended for use by healthcare professionals only.
About Datexim: Datexim is dedicated to advancing digital pathology through innovative solutions that improve diagnostic processes and ultimately enhance patient outcomes.